Jaguar Health Explores AI in Crofelemer Development for Intestinal Failure

Jaguar Health, Inc. (NASDAQ:JAGX) has announced plans to integrate AI platforms into its development and commercialization strategies for crofelemer, a treatment for intestinal failure. This initiative targets both adult and pediatric patients, especially those with microvillus inclusion disease (MVID), a rare and lethal condition lacking alternative treatments.

Dr. Pravin Chaturvedi, Jaguar's Chief Scientific Officer, highlighted AI's potential in creating personalized treatment regimens and establishing credible links between genetics and clinical manifestations. CEO Lisa Conte emphasized progress in their MVID programs, notably reducing parenteral support needs by up to 37% in trials. Jaguar is engaged in talks to secure non-dilutive funding, pursuing FDA Breakthrough Therapy designation to expedite regulatory submissions.